<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02579954</url>
  </required_header>
  <id_info>
    <org_study_id>1308156</org_study_id>
    <secondary_id>2014-A00169-38</secondary_id>
    <nct_id>NCT02579954</nct_id>
  </id_info>
  <brief_title>Cardiac Function and Exercise Capacity in Pulmonary Arterial Hypertension</brief_title>
  <acronym>FONCE-HTAP</acronym>
  <official_title>Cardiac Function and Exercise Capacity in Pulmonary Arterial Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pulmonary Arterial Hypertension is characterized by a progressive increase in pulmonary
      vascular resistance inducing shortness of breath and exercise intolerance. We aim to
      correlate cardiac function (evaluated at rest by right heart catheterism and RMN) to exercise
      capacity (evaluated by endurance time at 75% of maximal workout), in prevalent patients with
      pulmonary arterial hypertension, and their evolution at three and twelve months.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 6, 2015</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endurance time at 75% of the maximal workout (determinated during a cardiopulmonary exercise testing - CPET),</measure>
    <time_frame>12 months after the inclusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Right ventricular ejection fraction evaluated by RMN</measure>
    <time_frame>at 3 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary haemodynamics : measurements at right heart catheterism</measure>
    <time_frame>at 3 and 12 months</time_frame>
    <description>cardiac index (L/min/m²)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary haemodynamics : measurements at right heart catheterism</measure>
    <time_frame>at 3 and 12 months</time_frame>
    <description>pressure in the right atrium (mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary haemodynamics : measurements at right heart catheterism</measure>
    <time_frame>at 3 and 12 months</time_frame>
    <description>pulmonary resistance (uw)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary haemodynamics : measurements at right heart catheterism</measure>
    <time_frame>at 3 and 12 months</time_frame>
    <description>mean pulmonary arterial pressure (mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional class (NYHA classification)</measure>
    <time_frame>at 3 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 minutes walking distance (m)</measure>
    <time_frame>at 3 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional exercise capacity (oxygen consumption measurement during test)</measure>
    <time_frame>at 3 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (SF-36 scale)</measure>
    <time_frame>at 3 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to clinical worsening (months)</measure>
    <time_frame>at 3 and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rehabilitation</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Rehabilitation</intervention_name>
    <arm_group_label>intervention</arm_group_label>
    <other_name>Supervised rehabilitation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients

          -  Patients with Pulmonary Arterial Hypertension (idiopathic, heritable or due to
             anorexigens),

          -  Prevalent cases of pulmonary artery hypertension (≥ 6 months) confirmed by right heart
             catheterism,

          -  Stable for at least 3 months,

          -  Written consent.

        Exclusion Criteria:

          -  Patients unable to proceed with six-minute walk test or CPET, or with
             contra-indication to exercise evaluation (syncope, low cardiac index, etc).

          -  Exercise induced abnormality (evaluated during the initial CPET) precluding to further
             evaluation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurent BERTOLETTI, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Saint Etienne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laurent BERTOLETTI, MD PhD</last_name>
    <phone>0477127770</phone>
    <email>laurent.bertoletti@chu-st-etienne.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Besançon</name>
      <address>
        <city>Besancon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno DEGANO, MD PhD</last_name>
      <email>bruno.degano@univ-fcomte.fr</email>
    </contact>
    <investigator>
      <last_name>Marie France SERONDE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean Charles DALPHIN, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Malika BOUHADDI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>39609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francis COUTURAUD, MD PhD</last_name>
      <email>francis.couturaud@chu-brest.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Gabriel Montpied</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire DAUPHIN, MD</last_name>
      <email>cdauphin@chu-clermontferrand.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Sud de Grenoble</name>
      <address>
        <city>Echirolles</city>
        <zip>38130</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianne NOIRCLERC, MD</last_name>
      <email>mnoirclerc@chu-grenoble.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrien JANKOWSKI, MD</last_name>
      <email>AJankowski@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Gilbert FERRETTI, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gilles BARONE ROCHETTE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernard WUYAM, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hélène BOUVAIST, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christophe PISON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnaud BOURDIN, MD PhD</last_name>
      <email>a-bourdin@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Maurice HAYOT, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fares GOUZI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu de Saint Etienne</name>
      <address>
        <city>Saint Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent BERTOLETTI, MD PhD</last_name>
      <phone>0477127770</phone>
      <phone_ext>+33</phone_ext>
      <email>laurent.bertoletti@chu-st-etienne.fr</email>
    </contact>
    <investigator>
      <last_name>Frédéric COSTES, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre CROISILLE, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurence BISCH, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Baptiste GAULTIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabelle COURT FORTUNE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nathalie GLAS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frédéric ROCHE, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexie GATE MARTINET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irina ENACHE, MD</last_name>
      <email>irina.enache@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Matthieu CANUET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Evelyne LONSDORFER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stéphane DOUTRELEAU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 15, 2015</study_first_submitted>
  <study_first_submitted_qc>October 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2015</study_first_posted>
  <last_update_submitted>June 26, 2017</last_update_submitted>
  <last_update_submitted_qc>June 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

